
# FDA-Approved Oncology Drugs Reference
*Common cancer therapeutics and their indications*

## Targeted Therapies

### EGFR Inhibitors (NSCLC):
- **Osimertinib** (Tagrisso): 1st line EGFR+, T790M resistance
- **Erlotinib** (Tarceva): 1st line EGFR+
- **Gefitinib** (Iressa): 1st line EGFR+
- **Afatinib** (Gilotrif): 1st line EGFR+ (exon 19 del, L858R)
- **Amivantamab**: EGFR exon 20 insertions

### ALK Inhibitors:
- **Alectinib** (Alecensa): 1st line ALK+
- **Brigatinib** (Alunbrig): 1st/2nd line ALK+
- **Lorlatinib** (Lorbrena): ALK+ (any line, brain mets)
- **Crizotinib** (Xalkori): ALK+, ROS1+

### KRAS G12C Inhibitors:
- **Sotorasib** (Lumakras): KRAS G12C+ NSCLC (post 1 line)
- **Adagrasib** (Krazati): KRAS G12C+ NSCLC

### HER2-Directed:
- **Trastuzumab** (Herceptin): HER2+ breast, gastric
- **Pertuzumab** (Perjeta): HER2+ breast (combo with trastuzumab)
- **T-DM1** (Kadcyla): HER2+ breast (ADC)
- **T-DXd** (Enhertu): HER2+ breast, gastric, NSCLC (ADC)

### BRAF/MEK Inhibitors:
- **Dabrafenib + Trametinib**: BRAF V600E/K melanoma, NSCLC, thyroid
- **Vemurafenib** (Zelboraf): BRAF V600E melanoma
- **Encorafenib + Binimetinib**: BRAF V600E melanoma, CRC

---

## Immunotherapy (Checkpoint Inhibitors)

### PD-1 Inhibitors:
- **Pembrolizumab** (Keytruda):
  - NSCLC (PD-L1 ≥1%), melanoma, HNSCC
  - MSI-H/dMMR (tumor-agnostic)
  - TMB-H ≥10 mut/Mb (tumor-agnostic)
  
- **Nivolumab** (Opdivo):
  - Melanoma, NSCLC, RCC, Hodgkin, HNSCC
  - MSI-H/dMMR CRC

### PD-L1 Inhibitors:
- **Atezolizumab** (Tecentriq): NSCLC, SCLC, urothelial
- **Durvalumab** (Imfinzi): Stage III NSCLC (consolidation)

### CTLA-4 Inhibitors:
- **Ipilimumab** (Yervoy): Melanoma (mono or + nivolumab)

---

## Chemotherapy (Key Regimens)

### Platinum-Based:
- **Cisplatin/Carboplatin**: NSCLC, ovarian, cervical, bladder
- **Oxaliplatin**: Colorectal (FOLFOX)

### Taxanes:
- **Paclitaxel**: Breast, ovarian, NSCLC
- **Docetaxel**: Breast, NSCLC, prostate

### Antimetabolites:
- **Pemetrexed**: Non-squamous NSCLC
- **Gemcitabine**: Pancreatic, bladder, NSCLC
- **5-FU**: Colorectal (FOLFOX, FOLFIRI)

---

## Hormone Therapies

### Breast Cancer (HR+):
- **CDK4/6 Inhibitors**: Palbociclib, Ribociclib, Abemaciclib
  - + Aromatase inhibitor or Fulvestrant
- **Fulvestrant**: ER+ breast (2nd line)
- **Tamoxifen**: ER+ breast (pre/post-menopausal)

### Prostate Cancer:
- **Enzalutamide** (Xtandi): Castration-resistant prostate
- **Abiraterone** (Zytiga): Castration-resistant prostate

---

**Last Updated**: January 2025
**Source**: FDA Drug Labels, NCCN Compendia
